Form 4: Aligos Therapeutics Director Heather Preston Granted Stock Options

Aligos Therapeutics, Inc. Director Heather Preston was granted 5,860 stock options with an exercise price of $7.63, vesting over the next year.

Summary

• Heather Preston, a Director of Aligos Therapeutics, Inc. (ALGS), was granted stock options.
• The grant date for these options was June 25, 2025.
• A total of 5,860 stock options were granted.
• The exercise price for these options is $7.63 per share.
• The options will vest 100% on the earlier of the first anniversary of the grant date (June 25, 2026) or immediately prior to the Issuer's 2026 annual meeting of stockholders, subject to continuous service to the Issuer through such vesting date.
• The options expire on June 25, 2035.

Sentiment

Score: 5

Explanation: The document reports a routine stock option grant to a director, which is a standard compensation practice and does not inherently indicate positive or negative sentiment regarding the company's immediate prospects or financial health.

Positives

• The grant of stock options to Director Heather Preston aligns her interests with those of shareholders, incentivizing long-term performance and value creation.

Future Outlook

The stock options granted to Director Heather Preston are set to vest 100% on the earlier of June 25, 2026, or immediately prior to the Issuer's 2026 annual meeting, provided she maintains continuous service.

Industry Context

This Form 4 filing details an individual insider transaction, which is a routine disclosure for public companies regarding changes in beneficial ownership of securities by directors, officers, and significant shareholders. It does not provide information on broader industry trends or the competitive landscape.

Related Party Transactions

• The grant of 5,860 stock options to Heather Preston, a Director of Aligos Therapeutics, Inc., constitutes a related party transaction as it involves compensation to a member of the company's board.

Stakeholder Impact

• Shareholders: The grant aligns the director's interests with shareholders, potentially leading to better long-term performance, but also represents a potential future dilution if options are exercised.

Next Steps

• The stock options are scheduled to vest on the earlier of June 25, 2026, or prior to the 2026 annual meeting of stockholders, subject to continuous service.

Key Dates

Keywords

Aligos Therapeutics, ALGS, Stock Option, Director, Insider Transaction, Form 4, Equity Grant, Executive Compensation